1. Canada Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
SureNano Science Ltd.

SureNano Science Ltd.

SURE.CN
SureNano Science Ltd.CA flagCanadian Securities Exchange
0.15
CAD
- -
- -
3.59MMarket Cap
SureNano Science Ltd.
SURE.CN
(Canadian Securities Exchange)

Recent

price

0.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.06
-0.02
-0.01
- -
-0.01
Basic EPS, GAAP
- -
-0.03
-0.02
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
-0.01
-0.02
-0.02
0.02
Book Value per Share
- -
0.03
0.01
- -
- -
0.05
Tangible Book Value per Share
- -
20
21
21
21
23
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-6,209.71
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-6,214.79
- -
- -
- -
- -
Profit Margin (%)
1
1
- -
- -
- -
1
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
1
1
- -
- -
- -
1
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-188.3
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
24
34
Market Capitalization
4
2
8

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
- -
1
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
295.31%
Free Cash Flow
- -
- -
13.45%
Net Income, GAAP
- -
- -
-78.71%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Clean Science and Technology Limited (CLEAN.NS)
Platinum Industries Ltd (PLATIND.NS)
Guangdong Huiyun Titanium Industry Co., Ltd. (300891.SZ)
United Ethanol, LLC (UETH)
Goa Carbon Limited (GOACARBON.BO)
Linde India Limited (LINDEINDIA.NS)
Business
SureNano Science Ltd. engages in the sale and distribution of nanotechnology-based emulsifying compounds primarily for cannabis, hemp, and other oil-soluble active ingredient applications in Canada and the United States. The company offers its flagship SureNano surfactant, a ready-to-mix food-grade blend of six natural, GRAS-approved ingredients that serves as the base for high-performance nano-emulsions achieving 40-50 nanometer droplet sizes; these enable homogeneous, stable water-dispersible products with enhanced bioavailability, clarity, taste modulation via Free Flavor technology, full entourage effect preservation, and lymphatic pathway digestion to bypass liver metabolism for beverages, sprays, edibles, topicals, tinctures, and more, manufactured under license by Caldic International to global GMP standards. SureNano Science Ltd., founded in 2021 and headquartered at #350-1650 West 2nd Avenue, Vancouver, BC V6J 1H4, Canada, provides complementary services including supply chain support, facility setup packages with equipment procurement and training, and knowledge transfer for client production. In November 2025, the company entered a non-binding letter of intent to acquire GlucaPharm Inc., advancing due diligence on its GLP-1 drug development assets including the GEP-44 triple antagonist for obesity and diabetes treatments; it concurrently launched a private placement for up to $1,250,000 to fund operations, market exploration, and such strategic opportunities while holding exclusive distribution rights for SureNano in Canada and Colorado, USA.

Company News

APIChatGPT

  • globenewswire.com

    SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform